Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Other Rheumatic Conditions

2015 ACR/ARHP Annual Meeting: Research Lends Insight Into Osteoporosis Treatment, New Auto-Inflammatory Disease, Scleroderma

Thomas R. Collins  |  March 15, 2016

SAN FRANCISCO—Post-menopausal women with osteoporosis, previously treated with oral bisphosphonates, had greater increases in bone density when taking denosumab compared with zoledronic acid over a year’s time, according to a study presented at the 2015 ACR/ARHP Annual Meeting. The findings were discussed in the Discovery 2015 plenary session, which focused on new research. In the…

2015 ACR/ARHP Annual Meeting: Immune Mediators Can Impact Inflammatory Response

Susan Bernstein  |  March 15, 2016

SAN FRANCISCO—Inflammation can be either acute or chronic, and it’s the inflammatory responses that don’t shut down normally, or resolve, that cause tissue damage in rheumatic disease. “Resolution bridges the gap between acute inflammation and adaptive immunity,” said Derek W. Gilroy, PhD, head of the Centre for Clinical Pharmacology and Professor of Immunology at University…

Titanium Dioxide Additives May Boost Intestinal Inflammation

David Douglas  |  March 3, 2016

NEW YORK (Reuters Health)—Murine and other studies suggest that titanium dioxide (TiO2) nanoparticles, widely used as food additives and in drug formulations, may be involved in intestinal inflammation, according to Swiss researchers. As Dr. Gerhard Rogler told Reuters Health by email, “It seems that titanium dioxide nanoparticles are not harmful for a healthy person with…

Insight into Crosstalk Between Bone & Immune Systems

Lara C. Pullen, PhD  |  February 22, 2016

Osteoimmunology is an emerging field that focuses on the interaction between bone and the immune system. CD4+ T cells play an important role in the bone marrow and modulate the differentiation of bone-resorbing osteoclasts. This article reviews the role of CD4+ T cells as an osteoclastogenic population in inflammatory bowel disease…

Route of Iron Replacement Doesn’t Impact IBD Activity, Quality of Life

Laura Newman  |  February 20, 2016

NEW YORK (Reuters Health)—The route of iron replacement therapy alters the gut microbiome and metabolomics in patients with inflammatory bowel disease (IBD), but the route is unrelated to disease activity and quality of life, according to a new study. “Crohn’s disease patients are extremely fragile to disturbances and one might speculate about consequences in long-term…

APS: What Rheumatologists Should Know about Hughes Syndrome

Graham R.V. Hughes, MD, FRCP  |  February 17, 2016

The problem that dogs the work of all of those treating patients with antiphospholipid syndrome (APS) is the apparent lack of knowledge of the syndrome, both by the general public, as well as by swaths of the medical fraternity. Perhaps it was ever thus—a syndrome less than 40 years old could be described as new,…

2015 ACR/ARHP Annual Meeting: Metabolic Pathways Linked with Inflammatory Diseases

Susan Bernstein  |  February 16, 2016

SAN FRANCISCO—Metabolomics could one day be a treasure map of information about inflammation in rheumatic disease. There are many metabolic pathways to pursue for clues on how to reverse this damaging process. “All of these signaling pathways are interrelated and affect each other,” said Douglas J. Veale, MD, director of translational research at Dublin Academic…

Fungal Microbiota Dysbiosis Seen in Inflammatory Bowel Disease

Anne Harding  |  February 13, 2016

NEW YORK (Reuters Health)—Patients with inflammatory bowel disease (IBD) show imbalance in their fungal intestinal microbiota, according to new findings. “The fungal microbiota is a new actor to take into account in the pathogenesis of IBD and potentially in other diseases,” Dr. Harry Sokol of Hospital Saint-Antoine in Paris, an author of the new study,…

Gut-on-a-Chip Provides Insight into Microbiome & Intestinal Inflammation

Lara C. Pullen, PhD  |  February 8, 2016

Researchers have created a microdevice with Caco-2 intestinal epithelial cells to aid in studying the human gut microbiome’s role in homeostasis, immune modulation and pathology. Using this gut-on-a-chip, researchers were able to examine in detail the processes they think result in chronic intestinal inflammation…

Large Group Study of Systemic JIA Patients Provides Insight into Disease Pathology

Lara C. Pullen, PhD  |  January 25, 2016

In a large group genetic analysis, researchers identified an association between the class II HLA region, including HLA-DRB1*11, and systemic juvenile idiopathic arthritis (sJIA), implicating adaptive immune molecules in sJIA’s pathogenesis and reinforcing its unique genetic position among JIA subtypes…

  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • …
  • 35
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences